Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04134325 · ClinicalTrials.gov registry record · Early Phase 1
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
A Early Phase 1 study of Refractory Hodgkin Lymphoma and Relapsed Hodgkin Lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04134325 is a Early Phase 1 study of Refractory Hodgkin Lymphoma and Relapsed Hodgkin Lymphoma that is active but no longer recruiting, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 10 participants, below the 41-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04134325, a Early Phase 1 study of Refractory Hodgkin Lymphoma and Relapsed Hodgkin Lymphoma, is active but no longer recruiting, sponsored by UNC Lineberger Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
Study Locations (1)
North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2037-07-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04134325
The ClinicalTrials.gov registry entry for NCT04134325 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 11 other Refractory Hodgkin Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04134325 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04134325 about?
NCT04134325 is a clinical study titled "Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma". LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) cl...
What is the current status of trial NCT04134325?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-09-01. Estimated completion is 2037-07-07.
What conditions does trial NCT04134325 study?
This clinical trial studies the following conditions: Refractory Hodgkin Lymphoma, Relapsed Hodgkin Lymphoma.
What interventions are being tested in trial NCT04134325?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04134325?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04134325 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
RECRUITING · Phase 2
-
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
RECRUITING · Phase 2
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RECRUITING · Phase 1
-
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
RECRUITING · Phase 1
-
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Refractory Hodgkin Lymphoma
All registered trials for this condition
Relapsed Hodgkin Lymphoma
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.